Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Levocloperastine→

Levocloperastine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
132301-89-4
Molecular formula
C20H24ClNO
Molecular weight
329.9 g/mol
Drug class
Non-opioid antitussivecentral and peripheral cough-reflex suppressant
Mechanism of action
The levorotatory isomer of cloperastine. It has described central effects at the medullary cough centre and peripheral effects on tracheobronchial cough receptors. Mechanistic data remain limited; cloperastine also has antihistaminic and papaverine-like smooth-muscle effects.
Indications / reported uses
  • Symptomatic relief of non-productive cough associated with respiratory tract conditions in countries where levocloperastine-containing products are authorised.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11060423/ · https://pubmed.ncbi.nlm.nih.gov/?term=levocloperastine+clinical+trial · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Non-opioid antitussive; central and peripheral cough-reflex suppressant

Mechanism of action

The levorotatory isomer of cloperastine. It has described central effects at the medullary cough centre and peripheral effects on tracheobronchial cough receptors. Mechanistic data remain limited; cloperastine also has antihistaminic and papaverine-like smooth-muscle effects.

General use cases

  • Symptomatic relief of non-productive cough associated with respiratory tract conditions in countries where levocloperastine-containing products are authorised.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Levocloperastine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levocloperastine Permitted Daily Exposure (PDE) report (the Levocloperastine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levocloperastine Occupational Exposure Limit (OEL) report (the Levocloperastine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.